THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD


First patients dosed in...

Related Keywords

United States , Japan , New York , China , Netherlands , Smeeth , Kent , United Kingdom , Cambridge , Cambridgeshire , Americans , Fernando Martinez , Sharon Barr , Formoterol Fumarate , European Respiratory Society Congress , National Heart , Division Of Pulmonary , Global Initiative On Obstructive Lung Disease , Blood Institute , Centers For Disease , Astrazeneca , Global Initiative For Chronic Obstructive Lung Disease , International Investigator , Data Network , Harvard Medical School , Critical Care Medicine , Weill Cornell Medicine , New York Presbyterian Hospital , International Co Ordinating Investigator , Associate Physician , Executive Vice President , Important Safety , Astrazeneca Biopharmaceuticals , Rare Diseases , Study Evaluating , Formoterol Fumarate Metered Dosed Inhaler , Cardiopulmonary Outcomes , Chronic Obstructive Pulmonary Disease , Metered Dose Inhaler , Exercise Parameters , Eur Respir , Post Hoc Cohort Analysis , Respir Crit Care Med , Future Risk , United Kingdom Routine Health Care Data , Intj Chron Obstruct Pulmon , General Practice Based Population , Chronic Obstructive Pulmonary , Obstructive Lung Disease , Atherosclerosis Risk , Global Initiative , Chronic Obstructive Lung Disease , Disease Control , Leading Causes ,